Search

Introduction

In Aloha, Oregon, pioneering cancer treatment with High-dose IV Vitamin C is making waves. This potent therapy enhances the body's natural defenses, potentially attacking cancer cells while safeguarding healthy tissue. It's a complementary approach, offering patients a chance to improve outcomes alongside conventional treatments, boosting well-being within the serene Pacific Northwest.

Get your High Dose Vitamin C in Aloha today

  • Medicine Name: Supercee Inj
  • Salt Composition: Each ml. Contains Ascorbic Acid (Sodium) 500 mg
  • Manufacturer: Axle Formulations
  • Contain: 50 ml Vial

What is High-Dose IV Vitamin C?

Vitamin C, a nutrient we commonly associate with boosting immunity and fighting colds, has a lesser-known, yet potentially groundbreaking role in the field of cancer treatment. When administered in high doses intravenously, Vitamin C transcends its traditional image, emerging as a promising player in integrative oncology.

Unlike oral Vitamin C, high-dose IV Vitamin C achieves significantly higher blood levels of the vitamin. This method bypasses the digestive system, allowing for concentrations that are unattainable via oral intake. These elevated levels have been observed to exert a variety of effects beneficial in cancer care.

A pivotal aspect of high-dose IV Vitamin C is its dual nature: it’s thought to act as a pro-oxidant in the presence of cancer cells while maintaining its antioxidant properties in normal cells. This selective toxicity is crucial, as it implies potential cancer-fighting abilities without harming healthy cells. Research indicates that at these high concentrations, Vitamin C can generate the production of hydrogen peroxide, a substance harmful to cancer cells.

A study published in the “Journal of Translational Medicine” (2014) explored this phenomenon. Researchers observed that high doses of Vitamin C impaired cancer cell growth and increased the efficacy of chemotherapy in various cancer models. This synergy between Vitamin C and chemotherapy could herald a new approach in cancer treatment, offering hope for enhanced outcomes with reduced side effects.

In summary, high-dose IV Vitamin C presents a unique and innovative method in cancer treatment. It exemplifies the principles of integrative oncology, where traditional and alternative treatments converge for holistic patient care. While ongoing research continues to unveil its full potential, high-dose IV Vitamin C stands as a testament to the evolving landscape of cancer therapy, blending age-old nutrients with modern medical insights.

The Role of High-Dose IV Vitamin C in Cancer Treatment

The journey of Vitamin C from a simple immune booster to a potential ally in cancer treatment is nothing short of remarkable. High-dose intravenous (IV) Vitamin C, in particular, has garnered attention in the oncology community, not just as a supplementary treatment but as a significant component of integrative cancer therapy.

At the heart of its role in cancer treatment is its unique mechanism of action. High doses of IV Vitamin C are believed to produce a high concentration of hydrogen peroxide in and around cancer cells. Unlike normal cells, many cancer cells lack the ability to break down this hydrogen peroxide, making them more susceptible to damage and apoptosis (programmed cell death). This selective toxicity is a critical aspect, as it targets cancer cells while sparing healthy ones, a fundamental goal in cancer treatment.

Moreover, high-dose IV Vitamin C has shown promise in enhancing the effectiveness of conventional cancer therapies. For example, when used alongside chemotherapy, it may improve the efficacy of the drugs and reduce their toxic side effects. This synergistic effect can be a game-changer, offering patients a more tolerable treatment experience.

Another significant role of high-dose IV Vitamin C in cancer care is its impact on patients’ overall well-being. Cancer treatments can often be grueling, with side effects that significantly impact quality of life. Vitamin C, known for its antioxidant properties, may help in mitigating some of these effects, providing better tolerance to treatments and improving patients’ overall wellness.

Clinical trials and studies continue to explore the full potential of this treatment. Though not a standalone cure, its integration into cancer care represents a broader shift towards more personalized and holistic approaches. As research progresses, high-dose IV Vitamin C could redefine aspects of cancer treatment, offering a beacon of hope for many battling the disease.

In conclusion, high-dose IV Vitamin C is more than just a supplemental treatment in the fight against cancer. It’s a symbol of hope and innovation, representing a stride towards more patient-centered, holistic care in the realm of oncology.

  • Use of High-Dose IV Vitamin C: High-dose IV Vitamin C is being explored as a complementary therapy in breast cancer treatment. Its role is primarily seen in enhancing the effectiveness of chemotherapy and reducing its side effects. Vitamin C’s antioxidant properties may also help in mitigating oxidative stress associated with breast cancer progression.
  • Reference Paper: Impact of Intravenous Vitamin C Administration in Reducing Severity of Symptoms in Breast Cancer Patients During Treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177022/
  • Use of High-Dose IV Vitamin C: In lung cancer, particularly in stage 4 non-small cell lung cancer (NSCLC), high-dose IV Vitamin C has shown promising results when used in conjunction with standard chemotherapy and radiation treatments. The approach is considered safe and relatively inexpensive, potentially improving patient outcomes. High-dose Vitamin C achieves very high blood levels, which are believed to be toxic to cancer cells due to a disruption in their metabolism. This disruption causes an accumulation of hydrogen peroxide and other free radicals in cancer cells, leading to their death or increased sensitivity to radiation and chemotherapy. Preliminary findings from a phase 2 trial indicate a possible increase in overall survival.
  • Reference Paper: Carver College of Medicine study reports on the results of a phase 1 clinical trial and preliminary findings from a phase 2 trial in stage 4 NSCLC​​​​. https://medicine.uiowa.edu/content/high-dose-vitamin-c-proves-safe-and-well-tolerated-brain-and-lung-cancer-trials
  • Use of High-Dose IV Vitamin C: In the treatment of metastatic colorectal cancer (mCRC), high-dose IV Vitamin C has been examined in combination with FOLFOX ± bevacizumab chemotherapy. A phase 3 clinical trial investigated its efficacy as a first-line treatment. While the overall progression-free survival (PFS) and overall survival (OS) in the group receiving high-dose Vitamin C plus chemotherapy were not superior to the chemotherapy-only group, a notable benefit was observed in patients with mCRC harboring RAS mutations. This subgroup experienced significantly longer PFS with the addition of Vitamin C to chemotherapy. Despite these findings, high-dose Vitamin C in combination with chemotherapy did not significantly extend PFS in the overall patient population with mCRC.
  • Reference Paper: High-Dose Vitamin C Tends to Kill Colorectal Cancer with High MALAT1 Expression https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714606/
  • Use of High-Dose IV Vitamin C: Although specific clinical trials directly linking high-dose IV Vitamin C to prostate cancer treatment are not readily accessible, general literature suggests that high-dose IV Vitamin C is considered a promising treatment for various cancer types, including prostate cancer. The available evidence points to Vitamin C’s role as a multi-targeting agent in cancer therapy. It functions as a cancer-specific, pro-oxidative cytotoxic agent, an anti-cancer epigenetic regulator, and an immune modulator. These properties make it a powerful adjuvant in cancer treatment, acting synergistically with standard therapies and aiding in reducing chemotherapy-related side effects. However, the lack of strong clinical data and phase III studies specifically for prostate cancer indicates the need for more extensive research in this area.
  • Reference:High dose IV vitamin C for treatment of prostate adenocarcinoma https://www.sciencedirect.com/science/article/abs/pii/S2186495013000023
  • Use of High-Dose IV Vitamin C: While specific clinical trials focusing on high-dose IV Vitamin C as a treatment for gastric cancer are not readily available, there is evidence suggesting a potential benefit of Vitamin C intake in reducing the risk of gastric cancer. An umbrella review comparing high versus low intake of Vitamin C (ascorbic acid) found that a higher intake of Vitamin C was associated with a reduced risk of gastric cancer. This reduction was quantified as a 34% decrease in risk for those with the highest intake levels compared to the lowest. However, it is important to note that this data pertains to Vitamin C intake in general and may not directly translate to the effects of high-dose IV Vitamin C specifically in gastric cancer treatment.
  • Reference: High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02134-y
  • High doses of intravenous vitamin C are being investigated for their potential in treating liver cancer. Laboratory studies indicate its ability to decrease cell proliferation in hepatocellular (liver) cancer cells. This effect is attributed to mechanisms such as the generation of hydrogen peroxide and the disruption of iron metabolism. Early clinical trials suggest its safety and potential efficacy, particularly as an adjunct to standard cancer therapies and in reducing chemotherapy side effects. However, definitive conclusions about its effectiveness require further extensive clinical studies.

    Research Paper Link: Ascorbic Acid Inhibits Liver Cancer Growth and Metastasis in vitro and in vivo, Independent of Stemness Gene Regulation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422961/

  • There is ongoing research on the role of high-dose intravenous vitamin C (IVC) in the treatment of ovarian cancer. While the evidence is still limited, some studies suggest that IVC may have potential benefits in improving outcomes for ovarian cancer patients.
  • One study 1 found that high-dose parenteral ascorbate (vitamin C) enhanced the chemosensitivity of ovarian cancer cells and reduced the toxicity of chemotherapy. The study showed that intravenous ascorbate produced high concentrations of vitamin C in the blood and tissues, which selectively killed cancer cells without harming normal tissues. The combination of IVC with chemotherapy showed synergistic effects in inhibiting ovarian cancer in mouse models and reducing chemotherapy-associated toxicity in patients.
  • Another study 2 reported on two cases of advanced ovarian cancer where the addition of antioxidants, including high-dose oral and intravenous vitamin C, to chemotherapy resulted in positive outcomes. One patient had normalization of tumor markers and remained disease-free for several years, while the other patient had normalization of tumor markers and no evidence of recurrent disease.
  • While these studies provide preliminary evidence of the potential benefits of high-dose IVC in ovarian cancer, more research is needed to establish its effectiveness and safety. Randomized controlled trials with larger sample sizes are necessary to confirm these findings and determine the optimal dosage and treatment regimen.
  • In summary, high-dose intravenous vitamin C may have a role in improving outcomes for ovarian cancer patients. However, further research is needed to fully understand its potential benefits and establish its place in the standard treatment of ovarian cancer.
  • Reference: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy https://pubmed.ncbi.nlm.nih.gov/24500406/
  • There is growing interest in the role of high-dose intravenous vitamin C (IVC) as an adjunctive therapy in the treatment of head and neck cancer. Head and neck cancer is a challenging disease to treat, and patients often experience significant side effects from conventional treatments such as radiation and chemotherapy.

    Several studies have investigated the potential benefits of IVC in head and neck cancer patients. One systematic review 1 found that IVC may improve time to relapse, reduce tumor mass, and improve survival when used in combination with chemotherapy. Additionally, IVC has been shown to improve quality of life and reduce chemotherapy-related side effects such as fatigue, nausea, and depression.

    The mechanism of action of IVC in cancer treatment is not fully understood, but it is thought to involve its antioxidant properties and its ability to modulate the immune system. IVC acts as a potent antioxidant, neutralizing harmful free radicals that can damage cells and DNA. It also stimulates the production and activation of immune cells, which can help to fight cancer cells.

    It is important to note that the evidence supporting the use of IVC in head and neck cancer is still limited and more rigorous studies are needed to conclusively demonstrate its effectiveness. However, the existing studies suggest that IVC may have a role in improving outcomes and reducing side effects in head and neck cancer patients.

    In conclusion, high-dose intravenous vitamin C shows promise as an adjunctive therapy in the treatment of head and neck cancer. It may improve survival, reduce tumor mass, and improve quality of life in combination with chemotherapy. However, more research is needed to fully understand its mechanisms of action and to determine the optimal dosage and treatment regimen.

  • High-dose intravenous vitamin C (IVC) has been a topic of interest in the treatment of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of cancer with limited treatment options and a poor prognosis. Conventional therapies for PDAC often come with significant side effects and a decreased quality of life for patients. As a result, some patients turn to integrative medicine therapies, such as high-dose IVC, as an alternative option.

    Studies have shown that high-dose IVC has the potential to be a promising multi-targeting agent in the treatment of cancer. It has been found to have anti-cancer effects, acting as a pro-oxidative cytotoxic agent, an anti-cancer epigenetic regulator, and an immune modulator. High-dose IVC can also act synergistically with standard chemotherapy, enhancing its effectiveness and reducing toxic side effects.

    While there is still a need for more extensive clinical data and phase III studies, early phase clinical trials have confirmed the safety and indicated the efficacy of high-dose IVC in eradicating tumor cells in various cancer types. In the case of PDAC, there have been reports of patients achieving objective regression of their disease and improved quality of life with high-dose IVC as an exclusive chemotherapeutic regimen.

    However, it is important to note that the use of high-dose IVC in advanced-stage cancer patients is still a topic of debate. Some studies have not found positive effects in human studies with advanced-stage cancer patients, and the rationale for using high-dose IVC to enhance chemotherapy effectiveness and reduce toxicity is not well-supported.

    In conclusion, while high-dose IVC shows promise as a potential adjunctive therapy for pancreatic cancer, more research is needed to fully understand its effectiveness and determine its role in the treatment of this aggressive disease.

    Reference: Treatment of pancreatic cancer with intravenous vitamin C: a case report https://pubmed.ncbi.nlm.nih.gov/29438178/

Conclusion

The exploration of high-dose intravenous vitamin C (IVC) in cancer treatment reveals a promising, yet complex landscape. Laboratory and some clinical studies suggest that IVC can impede cell proliferation in various cancer types, including cervical and liver cancer, through mechanisms such as generating hydrogen peroxide and disrupting iron metabolism. Additionally, early phase clinical trials indicate that IVC is generally well-tolerated and may enhance the efficacy of conventional cancer therapies, contributing to improved patient quality of life and reduced toxicities associated with chemotherapy. However, the current body of evidence, while indicative of potential benefits, lacks the robustness of large-scale phase III clinical trials. Thus, while high-dose IVC emerges as a compelling adjunct in cancer treatment, further rigorous research is essential to fully understand its role and efficacy in oncology.

Back to Top
Product has been added to your cart
× We're here to help